Alto Neuroscience (ANRO) Free Cash Flow (2023 - 2026)
Alto Neuroscience (ANRO) posted Free Cash Flow of -$28.0 million for Q1 2026, down 143.42% sequentially from -$11.5 million in Q4 2025, and down 69.07% YoY from -$90.6 million in Q1 2025.
Alto Neuroscience (ANRO) Free Cash Flow (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported Free Cash Flow for 4 years, with the latest figure at -$28.0 million in Q1 2026.
- Quarterly Free Cash Flow fell 69.07% year-over-year to -$28.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$63.2 million (down 19.79% YoY) and the FY2025 annual result came in at -$51.8 million, down 9.21% from the prior year.
- Free Cash Flow fell to -$28.0 million in Q1 2026 per ANRO's latest filing, from -$11.5 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$6.7 million in Q2 2023 and troughed at -$28.0 million in Q1 2026.
- A 4-year average of -$12.4 million and a median of -$11.5 million in 2025 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow slumped 79.34% in 2024, then climbed 11.4% in 2025.
- Over 4 years, Free Cash Flow stood at -$12.0 million in 2023, then dropped by 8.3% to -$13.0 million in 2024, then advanced by 11.34% to -$11.5 million in 2025, then sank by 143.42% to -$28.0 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$28.0 million, -$11.5 million, and -$9.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - | -19.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.76 Mn |
| Jun 30, 2026 | -19.76 Mn |
| Mar 31, 2026 | -28.03 Mn |
| Mar 31, 2026 | -28.03 Mn |
| Dec 31, 2025 | -11.52 Mn |
| Dec 31, 2025 | -11.52 Mn |
| Sep 30, 2025 | -9.92 Mn |
| Sep 30, 2025 | -9.92 Mn |
| Jun 30, 2025 | -13.78 Mn |
| Jun 30, 2025 | -13.78 Mn |
| Mar 31, 2025 | -16.58 Mn |
| Mar 31, 2025 | -16.58 Mn |
| Dec 31, 2024 | -12.99 Mn |
| Dec 31, 2024 | -12.99 Mn |
| Sep 30, 2024 | -11.19 Mn |
| Sep 30, 2024 | -11.19 Mn |
| Jun 30, 2024 | -12.03 Mn |
| Jun 30, 2024 | -12.03 Mn |
| Mar 31, 2024 | -11.21 Mn |
| Mar 31, 2024 | -11.21 Mn |